---
title: "Lysergide (DT120) in Generalized anxiety disorder: Panorama"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Panorama. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 87 evidence topics quoted from 21 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence/panorama"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Panorama

<a id="heading-3.1.2"></a>

## 3.1.2 Panorama

<a id="heading-3.1.2.1"></a>

### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

#### Main objective in the EU trial record

> “Double-blind Period (Part A): To evaluate the efficacy of a single dose of 100 μg MM120 versus placebo on anxiety symptoms in adults with GAD”

Source: [CTIS 2024-513572-17-00](https://euclinicaltrials.eu/ctis-public/view/2024-513572-17-00)

<a id="topic-3.1.2.1-2"></a>

#### Registered study purpose and official title

> “A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40 Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral MM120 Compared to Placebo in the Treatment of Adults With Generalized Anxiety Disorder - Panorama”
> “A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Generalized Anxiety Disorder - Panorama”

Source: [ClinicalTrials.gov NCT06809595](https://clinicaltrials.gov/study/NCT06809595)

<a id="topic-3.1.2.1-3"></a>

#### Objective stated by the sponsor

> “Panorama (MM120-301) is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of DT120 Orally Disintegrating Tablet (ODT) in adults with generalized anxiety disorder (GAD).”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-3.1.2.1-4"></a>

#### Objectives of Part A and Part B across the phase 3 trials

> “Part A evaluated acute efficacy and safety over 12 weeks following a single administration of DT120”
> “Part B evaluated the maintenance of efficacy and safety and retreatment patterns over an additional 40 weeks”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="heading-3.1.2.2"></a>

### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

#### Study dates in the registry

| Milestone | Registry record |
| --- | --- |
| Study start (actual) | “2025-01-29” |
| Primary completion (actual) | “2026-08-13” |
| Study completion (estimated) | “2027-05” |
| First posted | “2025-02-05” |
| Last update posted | “2026-09-04” |

Source: [ClinicalTrials.gov NCT06809595](https://clinicaltrials.gov/study/NCT06809595)

<a id="topic-3.1.2.2-2"></a>

#### Registered locations

> “This study has 36 locations”

Source: [ClinicalTrials.gov NCT06809595](https://clinicaltrials.gov/study/NCT06809595)

<a id="topic-3.1.2.2-3"></a>

#### Registry status and results posting

> “Active, not recruiting”
> “No Results Posted”

Source: [ClinicalTrials.gov NCT06809595](https://clinicaltrials.gov/study/NCT06809595)

<a id="topic-3.1.2.2-4"></a>

#### Study centers reported by the sponsor

> “Panorama enrolled 245 participants across approximately 32 study centers.”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-3.1.2.2-5"></a>

#### Conduct in the United States and Europe

> “The Panorama study will evaluate the efficacy and safety of MM120 ODT versus placebo, will be conducted in the United States and Europe, and is expected to enroll approximately 250 participants.”

Source: [MindMed Panorama first patient dosed announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/171/mindmed-announces-first-patient-dosed-in-panorama-the-second-pivotal-phase-3-study-of-mm120-in-generalized-anxiety-disorder)

<a id="topic-3.1.2.2-6"></a>

#### EU member states and trial start

> “France, Poland, Germany, Czechia”
> “Start of trial 20/08/2025”

Source: [CTIS 2024-513572-17-00](https://euclinicaltrials.eu/ctis-public/view/2024-513572-17-00)

<a id="topic-3.1.2.2-7"></a>

#### EU member state decision, trial start, and recruitment dates

| Member state | Decision date | Trial start | Recruitment start | Recruitment end |
| --- | --- | --- | --- | --- |
| Germany | “19/02/2025” | “21/08/2025” | “04/09/2025” | “15/05/2026” |
| France | “20/02/2025” | “26/09/2025” | “22/12/2025” | “15/05/2026” |
| Czech Republic | “24/02/2025” | “20/08/2025” | “02/09/2025” | “15/05/2026” |
| Poland | “02/03/2025” | “25/09/2025” | “03/10/2025” | “15/05/2026” |

Source: [CTIS 2024-513572-17-00](https://euclinicaltrials.eu/ctis-public/view/2024-513572-17-00)

<a id="topic-3.1.2.2-8"></a>

#### EU estimated global end date

> “Estimated global end date of the trial:”
> “25/05/2027”

Source: [CTIS 2024-513572-17-00](https://euclinicaltrials.eu/ctis-public/view/2024-513572-17-00)

<a id="topic-3.1.2.2-9"></a>

#### First participant dosed, January 2025

> “today announced that the first patient has been dosed in Panorama, its second Phase 3 study evaluating MM120 ODT, a proprietary, pharmaceutically optimized form of LSD for the treatment generalized anxiety disorder (GAD).”

Source: [MindMed Panorama first patient dosed announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/171/mindmed-announces-first-patient-dosed-in-panorama-the-second-pivotal-phase-3-study-of-mm120-in-generalized-anxiety-disorder)

<a id="topic-3.1.2.2-10"></a>

#### Enrollment completion

> “Completed enrollment of Phase 3 Panorama study (GAD) with 245 participants randomized 2:1:2 to receive DT120 ODT 100 µg, DT120 ODT 50 µg control, or placebo.”

Source: [Definium Therapeutics second quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/242/definium-therapeutics-reports-second-quarter-2026-financial-results-and-recent-highlights)

<a id="topic-3.1.2.2-11"></a>

#### Topline results of Part A reported September 14, 2026

> “On September 14, 2026, we announced that the Panorama study met its primary endpoint and all key secondary efficacy endpoints”

Source: [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm)

<a id="topic-3.1.2.2-12"></a>

#### Topline timing: September 2026, August 2026, superseded by results reported in September 2026

> “Panorama results anticipated September 2026”
> “Topline data anticipated in September 2026.”

Source: [Definium Therapeutics second quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/242/definium-therapeutics-reports-second-quarter-2026-financial-results-and-recent-highlights)

> “With our Panorama topline results in GAD expected in September, we remain focused on bringing this potential new treatment to patients as quickly as possible.”

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-3.1.2.2-13"></a>

#### Topline timing: late third quarter of 2026, April 2026, superseded in August 2026

> “Topline data now anticipated in late 3Q 2026 (updated from 2H 2026).”

Source: [Definium Therapeutics Investor and Analyst Day announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/223/definium-therapeutics-highlights-dt120-odt-lysergide-tartrate-clinical-advancements-and-commercial-strategy-at-investor-and-analyst-day)

> “Topline data expected in late 3Q 2026 (updated from 2H 2026).”

Source: [Definium Therapeutics first quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/225/definium-therapeutics-reports-first-quarter-2026-financial-results-and-recent-highlights)

<a id="topic-3.1.2.2-14"></a>

#### Topline timing: second half of 2026, January 2025, superseded in April 2026

> “Topline data from the 12-week double-blind period anticipated in the second half of 2026”

Source: [MindMed Panorama first patient dosed announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/171/mindmed-announces-first-patient-dosed-in-panorama-the-second-pivotal-phase-3-study-of-mm120-in-generalized-anxiety-disorder)

> “Topline data from the 12-week double-blind period (Part A) is anticipated in the second half of 2026.”

Source: [MindMed full-year 2024 results announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/175/mindmed-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-business-updates)

> “Enrollment is on track in the Panorama study, the Company’s second Phase 3 study of MM120 ODT for the treatment of GAD.”
> “Topline data from the 12-week double-blind period (Part A) is anticipated in the second half of 2026.”

Source: [MindMed third quarter 2025 results announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/203/mindmed-reports-q3-2025-financial-results-and-business-updates)

> “2H 2026: Topline data from Panorama – the second Phase 3 study of DT120 ODT in GAD”

Source: [Definium Therapeutics rebrand announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/207/mindmed-rebrands-to-definium-therapeutics-advancing-a-leading-late-stage-psychiatry-pipeline-with-three-phase-3-readouts-expected-in-2026)

> “Panorama: study enrollment on track with topline data anticipated in 2H 2026.”

Source: [Definium Therapeutics full-year 2025 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/215/definium-therapeutics-reports-full-year-2025-financial-results-and-business-updates)

> “In January 2025, we announced the initiation of Panorama, with an anticipated topline readout (Part A results) in the second half of 2026.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

<a id="heading-3.1.2.3"></a>

### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

#### Phase 3 randomized, double-blind, placebo-controlled design with an open-label extension

> “The study consists of a 12-week double-blind treatment period (Part A) followed by a 40-week open-label extension (Part B), during which participants may be eligible to receive up to four additional doses of DT120 ODT 100 μg based on symptom severity, for a total study duration of approximately 56 weeks.”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

> “The study consists of a 12-week randomized, double-blind, single-dose administration period evaluating DT120 versus placebo, followed by a 40-week extension phase with the opportunity for open-label treatment. During this phase, participants will be monitored and evaluated for potential treatment with DT120 based on pre-specified safety and symptom severity criteria.”

Source: [ClinicalTrials.gov NCT06809595](https://clinicaltrials.gov/study/NCT06809595)

<a id="topic-3.1.2.3-2"></a>

#### Design aligned with Voyage

> “The clinical trial design of the 52-week Panorama study is aligned to Voyage and will be conducted in two parts: Part A, a 12-week, randomized, double-blind, placebo-controlled, parallel-group period; and Part B, a 40-week extension period during which participants will be eligible for open-label treatment with MM120 ODT based on symptom severity.”

Source: [MindMed Panorama first patient dosed announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/171/mindmed-announces-first-patient-dosed-in-panorama-the-second-pivotal-phase-3-study-of-mm120-in-generalized-anxiety-disorder)

<a id="topic-3.1.2.3-3"></a>

#### Randomization ratio and the 50 µg arm

> “Eligible participants were randomized 2:1:2 to receive a single dose of DT120 ODT 100 µg, DT120 ODT 50 µg, or matching placebo, with the 50 µg arm included to help mitigate functional unblinding.”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

> “The 50 µg arm serves to confound participants’ ability to accurately assess the dose condition to which they have been randomized. This approach builds on the MM120 Phase 2b study, which the Company believes demonstrated that the clinical activity of MM120 was not attributable to functional unblinding and aligns with FDA guidance regarding the use of complementary designs across our Phase 2 and 3 studies.”

Source: [MindMed Panorama first patient dosed announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/171/mindmed-announces-first-patient-dosed-in-panorama-the-second-pivotal-phase-3-study-of-mm120-in-generalized-anxiety-disorder)

> “Voyage and Emerge established a 2-arm framework of DT120 100 μg versus placebo to characterize target dose efficacy and safety. Panorama and Ascend added DT120 50 μg as a low-dose comparator, thereby creating a 3-arm framework to evaluate efficacy and safety as well as mitigate functional unblinding”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-3.1.2.3-4"></a>

#### Statistical comparisons limited to 100 µg versus placebo

> “Statistical analyses & endpoints only compare 100 µg vs placebo”
> “Panorama included a DT120 ODT 50 µg control arm (n=52) that was not designed or powered for statistical comparisons.”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.3-5"></a>

#### Registry design fields

| Field | Registry record |
| --- | --- |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Triple” |
| Phase | “Phase 3” |
| Arm 1 | “Placebo Comparator: Arm 1 - Placebo” |
| Arm 2 | “Sham Comparator: Arm 2 - 50µg DT120” |
| Arm 3 | “Experimental: Arm 3 - 100µg DT120” |

Source: [ClinicalTrials.gov NCT06809595](https://clinicaltrials.gov/study/NCT06809595)

<a id="topic-3.1.2.3-6"></a>

#### Adaptive design with blinded sample size re-estimation

> “Both trials use an adaptive trial design with a blinded interim SSRE, allowing for an increase in sample size by up to 50% in each trial depending on the observed values for certain nuisance parameters.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

<a id="topic-3.1.2.3-7"></a>

#### Blinding, central raters, and dosing session monitors

> “Participants, DSMs, central raters, and dosing sites were blinded to treatment and primary endpoint data”
> “HAM-A (GAD) or MADRS (MDD) central raters were independent from the dosing site and blinded to treatment and visit number”
> “Site raters could not serve as the DSM or HCP for the same participant after the screening or baseline assessments to mitigate functional unblinding”
> “Baseline expectancy was measured in participants, and perceived treatment was recorded for both participants and central raters”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

> “In Panorama, HAM-A ratings were assessed by central raters blinded to both treatment assignment and visit number.”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.3-8"></a>

#### Symptom-triggered open-label treatment in Part B

> “Open-label treatment in Part B was based on prespecified symptom severity, which allowed for assessment of retreatment patterns and durability of response in a real-world fashion”
> “To maintain data integrity, participants who met retreatment thresholds and had no safety concerns were required to re-treat”
> “Total of up to 5 doses over 52-week period with final dose no later than week 50.”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

> “GAD-7 (ePRO): biweekly”
> “HAM-A (central rater): monthly or when GAD-7 ≥ 10”
> “Eligible for open-label treatment if HAM-A ≥ 16”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="heading-3.1.2.4"></a>

### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

#### Population enrolled

> “The study enrolled participants 18 to 74 years of age with a DSM-5-confirmed primary diagnosis of GAD and a minimum Hamilton Anxiety Rating Scale (HAM-A) total score of 20 at screening and baseline.”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-3.1.2.4-2"></a>

#### Registered inclusion and exclusion criteria

> “Diagnosis of GAD per DSM-5”
> “Male or female aged 18 to 74”
> “HAM-A Total Score ≥20”
> “Certain psychiatric disorders (other than generalized anxiety disorder)”
> “First degree relative with or lifetime history of a psychotic disorder or bipolar disorder”
> “Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine)”
> “Any clinically significant unstable illness”
> “without clinically relevant medical or psychiatric history”

Source: [ClinicalTrials.gov NCT06809595](https://clinicaltrials.gov/study/NCT06809595)

<a id="topic-3.1.2.4-3"></a>

#### Key inclusion and exclusion criteria for Voyage and Panorama

| Criterion type | Criterion |
| --- | --- |
| Inclusion | “Age 18–74 years” |
| Inclusion | “GAD diagnosis based on DSM-5 and confirmed by MINI” |
| Inclusion | “HAM-A total score ≥20 at screening and baseline” |
| Inclusion | “MADRS items 1, 7, and 8 score ≤3 at screening and baseline” |
| Inclusion | “Use of highly effective methods of contraception” |
| Exclusion | “Contraindicated medical or psychiatric conditions” |
| Exclusion | “Systematic psychotherapy ≤4 weeks prior to screening or plans to initiate therapy” |
| Exclusion | “Use of prohibited concomitant medications, supplements, or other therapeutics” |
| Exclusion | “>10 instances of psychedelics use in the past 5 years and any use in the past 2 years” |

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-3.1.2.4-4"></a>

#### Amendment of the prior psychedelic use criterion

> “Exclusion criteria related to prior use of psychedelics was later amended to any lifetime use of psychedelics based on FDA feedback.”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-3.1.2.4-5"></a>

#### Independent confirmation of eligibility

> “Eligibility criteria were reviewed independently by site personnel, central raters, and medical monitors, thereby enhancing diagnostic accuracy and reducing site-level variability”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-3.1.2.4-6"></a>

#### Exclusion of a current major depressive episode

> “Eligibility criteria excluded participants currently in a major depressive episode.”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.4-7"></a>

#### Age range in the EU trial record

> “18-64 years, 65+ years”

Source: [CTIS 2024-513572-17-00](https://euclinicaltrials.eu/ctis-public/view/2024-513572-17-00)

<a id="heading-3.1.2.5"></a>

### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

#### Study drug and placebo in the registry

> “A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)”
> “lysergide tartrate”
> “LSD D-Tartrate”
> “A substance that is designed to have no therapeutic value”

Source: [ClinicalTrials.gov NCT06809595](https://clinicaltrials.gov/study/NCT06809595)

<a id="topic-3.1.2.5-2"></a>

#### Single dose in Part A

| Arm | Part A treatment |
| --- | --- |
| DT120 ODT 100 µg | “DT120 ODT 100 µg” |
| DT120 ODT 50 µg | “DT120 ODT 50 µg control” |
| Placebo | “Placebo” |
| Dosing in Part A | “Single Dose” |

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.5-3"></a>

#### Open-label DT120 ODT 100 µg in Part B

> “40-week extension with opportunity for open-label DT120 100 µg based on protocol-defined symptom and safety criteria; up to 4 Part B doses (max 5 total doses over 52 weeks)”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-3.1.2.5-4"></a>

#### Dosing session monitoring and end-of-session checklist

> “Participants were monitored for a minimum of 8 hours on dosing day and were assessed hourly beginning 5 hours after dosing on a structured end-of-session checklist (EoSC).”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

> “Two qualified and trained DSMs monitored dosing, with the second DSM having the option to monitor remotely via video.”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-3.1.2.5-5"></a>

#### No psychotherapy

> “Psychotherapy was prohibited during dosing sessions. Standardized EoSC was used to assess participant status and ability to end the dosing session”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

> “No psychotherapeutic intervention beyond study drug”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="heading-3.1.2.6"></a>

### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

#### 3.1.2.6.1 Rationale for Using Hamilton Anxiety Rating Scale Total Score as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

##### Primary endpoint and sponsor rationale for Week 12

> “The primary endpoint of Panorama will measure the change from baseline in HAM-A at Week 12 between MM120 ODT 100 µg and placebo, which is consistent with the durable clinical effect observed in the MM120 Phase 2b study.”

Source: [MindMed Panorama first patient dosed announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/171/mindmed-announces-first-patient-dosed-in-panorama-the-second-pivotal-phase-3-study-of-mm120-in-generalized-anxiety-disorder)

<a id="topic-3.1.2.6.1-2"></a>

##### Registered primary outcome and HAM-A scoring

> “Change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) total score at Week 12”
> “The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.”

Source: [ClinicalTrials.gov NCT06809595](https://clinicaltrials.gov/study/NCT06809595)

> “The HAM-A is a 14-item clinician-rated outcome measure assessing various domains of anxiety with a range of 0-56.”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.6.1-3"></a>

##### FDA guidance on a 12-week double-blind endpoint and blinded central raters

> “Before an initial application for a product intended for the treatment of a chronic illness such as post-traumatic stress disorder or major depressive disorder, sponsors should evaluate with a double-blind design the effect of treatment at 12 weeks.”
> “Sponsors should continue to follow subjects beyond the Week 12 endpoint to monitor for symptom recurrence or, potentially, the need for repeat dosing.”
> “Sponsors should incorporate the use of central raters blinded to treatment allocation and visit number.”

Source: [FDA psychedelic drugs clinical investigations guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="topic-3.1.2.6.1-4"></a>

##### Minimal clinically important difference used in the phase 2b trial

> “The minimal clinically important difference was 2.5 points.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.2.6.1-5"></a>

##### Sponsor target product profile for the HAM-A difference

> “Dashed line represents target product profile: durable efficacy of 4 points or greater”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.6.1-6"></a>

##### Key secondary multiplicity-controlled endpoints

> “The primary endpoint is change from baseline in HAM-A total score at Week 12. Key secondary multiplicity-controlled endpoints are change from baseline in Clinical Global Impression-Severity (CGI-S) scale score at Week 12, change from baseline in HAM-A total score at Week 1, and change from baseline in CGI-S score at Day 2.”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

> “The CGI-S is a clinician-rated outcome measure assessing overall severity of illness with a range of 1 to 7.”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.6.1-7"></a>

##### Other registered secondary outcomes in Part A

> “HAM-A response (reduction from Baseline score of ≥50%) at each timepoint assessed during the 12-week double-blind period”
> “HAM-A remission (total score ≤7) at each timepoint assessed during the 12-week double-blind treatment period”
> “Clinical Global Impression - Improvement (CGI-I) Scale score at each timepoint assessed during the 12-week double-blind period”
> “Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in Patient Global Impression - Severity (PGI-S) Scale score”
> “Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in - Montgomery-Åsberg Depression Rating Scale (MADRS) total score”
> “Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in - Work Productivity and Activity Impairment Specific Health Problem Questionnaire (WPAI-SHP)”
> “Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in - EuroQol-5 Dimensions - 5 Levels (EQ-5D-5L)”
> “Change from Baseline in the Changes in Sexual Functioning Questionnaire (CSFQ-14) total score at each timepoint assessed during the double-blind period”

Source: [ClinicalTrials.gov NCT06809595](https://clinicaltrials.gov/study/NCT06809595)

<a id="topic-3.1.2.6.1-8"></a>

##### Registered secondary outcomes in Part B

> “Percent of participants requiring one, two, three, four, or five doses of DT120 during the 52-week study (Part A and Part B) as assessed by participants meeting protocol-specified retreatment criteria during the 40-week open-label period”
> “Time to first treatment or lack of efficacy in the open-label period (Part B)”
> “Need for DT120 treatment as assessed by the average number of DT120 treatments during the study”
> “HAM-A response (reduction from Baseline score of ≥50%) at each timepoint assessed during the 40-week open-label period”
> “HAM-A remission (total score ≤7) at each timepoint assessed during the 40-week open-label period”

Source: [ClinicalTrials.gov NCT06809595](https://clinicaltrials.gov/study/NCT06809595)

<a id="heading-3.1.2.7"></a>

### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

#### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

##### Participants randomized

> “Panorama enrolled 245 participants across approximately 32 study centers.”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

| Group | Participants randomized |
| --- | --- |
| DT120 ODT 100 µg | “n=96” |
| DT120 ODT 50 µg control | “n=52” |
| Placebo ODT | “n=97” |
| Total | “n=245” |

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.7.1-2"></a>

##### Enrollment in the registry

| Field | Registry record |
| --- | --- |
| Enrollment (actual) | “245” |
| Planned maximum in the detailed description | “The study will enroll up to 375 participants aged 18 to 74 years” |

Source: [ClinicalTrials.gov NCT06809595](https://clinicaltrials.gov/study/NCT06809595)

<a id="topic-3.1.2.7.1-3"></a>

##### Participants analyzed in the ITT and safety populations

> “Safety population (n=244)”
> “ITT population (n=245)”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.7.1-4"></a>

##### Planned enrollment: target of 200 participants after blinded sample size re-estimation, April 2026, superseded in August 2026

> “Panorama: Blinded sample size re-estimation complete with total target enrollment updated to 200 participants. Current enrollment over 200 participants and screening now closed.”

Source: [Definium Therapeutics Investor and Analyst Day announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/223/definium-therapeutics-highlights-dt120-odt-lysergide-tartrate-clinical-advancements-and-commercial-strategy-at-investor-and-analyst-day)

> “Completed the blinded sample size re-estimation for Panorama (GAD) with total target enrollment updated to 200 participants. Current enrollment is over 200 participants, and screening has been closed.”

Source: [Definium Therapeutics first quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/225/definium-therapeutics-reports-first-quarter-2026-financial-results-and-recent-highlights)

<a id="topic-3.1.2.7.1-5"></a>

##### Planned enrollment: approximately 250 participants, January 2025, superseded in April 2026

> “The Panorama study will evaluate the efficacy and safety of MM120 ODT versus placebo, will be conducted in the United States and Europe, and is expected to enroll approximately 250 participants.”

Source: [MindMed Panorama first patient dosed announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/171/mindmed-announces-first-patient-dosed-in-panorama-the-second-pivotal-phase-3-study-of-mm120-in-generalized-anxiety-disorder)

> “Panorama is expected to enroll approximately 250 participants (randomized 2:1:2 to receive MM120 ODT 100 µg, MM120 ODT 50 µg or placebo) in the U.S. and Europe.”

Source: [MindMed full-year 2024 results announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/175/mindmed-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-business-updates)

> “Panorama is expected to enroll approximately 250 participants (randomized 2:1:2 to receive MM120 ODT 100 µg, MM120 ODT 50 µg control, or placebo) in the U.S. and Europe.”

Source: [MindMed third quarter 2025 results announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/203/mindmed-reports-q3-2025-financial-results-and-business-updates)

> “Panorama is expected to enroll approximately 250 participants, in the U.S. and Europe, randomized 2:1:2 to receive DT120 ODT 100 µg, DT120 ODT 50 µg control, or placebo.”

Source: [Definium Therapeutics full-year 2025 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/215/definium-therapeutics-reports-full-year-2025-financial-results-and-business-updates)

> “Panorama is anticipated to enroll approximately 250 participants (randomized 2:1:2 to receive DT120 ODT 100 µg, DT120 ODT 50 µg or placebo).”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

<a id="heading-3.1.2.7.2"></a>

#### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

##### Primary analysis population and model

> “Primary endpoint of the study was change in HAM-A at week 12 between 100 µg and placebo using a Mixed-Effects Model Repeated Measures (MMRM) statistical analysis with reference-based imputation.”
> “ITT population. Placebo-adjusted HAM-A at week 12 using a Mixed-Effects Model Repeated Measures (MMRM) statistical analysis with reference-based imputation.”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.7.2-2"></a>

##### Multiplicity control of key secondary endpoints

> “Includes the primary endpoint and all hierarchically controlled key secondary endpoints.”
> “Key secondary endpoints of the study was change in CGI-S at day 2 and week 12 between 100 µg and placebo using a Mixed-Effects Model Repeated Measures (MMRM) statistical analysis with reference-based imputation.”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.7.2-3"></a>

##### Response and remission analyses

> “ITT population. Pre-planned secondary endpoints.”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.7.2-4"></a>

##### Safety population

> “Safety population in study part A (through week 12).”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.7.2-5"></a>

##### Subgroup analyses

> “Subgroup analysis of ITT population; 100 µg and placebo groups only.”
> “For each subgroup, the change from baseline in HAM-A total score is analyzed using the same MMRM model as the primary efficacy analysis. If the number of patients is small for a subgroup, the treatment difference will not be stable as it would be highly sensitive to outliers.”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.7.2-6"></a>

##### Part B interim analysis populations

> “Based on interim analysis as of August 11, 2026. Interim analysis based on partial data and subject to change.”
> “ITT population who entered Part B. Data based on Week 12 in Part A.”
> “ITT Part A+B population with treatment policy strategy.”
> “50 µg cohort not included due to small n.”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="heading-3.1.2.8"></a>

### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

#### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

##### Part A disposition

| Group | Randomized | ITT population | Completed Part A |
| --- | --- | --- | --- |
| DT120 ODT 100 µg | “n=96” | “100% included in ITT population” | “90% completed Part A” |
| DT120 ODT 50 µg control | “n=52” | “100% included in ITT population” | “87% completed Part A” |
| Placebo ODT | “n=97” | “100% included in ITT population” | “90% completed Part A” |

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.8.1-2"></a>

##### Overall discontinuation in Part A

> “Overall discontinuation rates were similar between DT120 ODT 100 μg, DT120 50 μg, and placebo groups (10.4%, 11.5%, and 10.3%).”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-3.1.2.8.1-3"></a>

##### Part B disposition at the interim analysis of August 11, 2026

| Part A group | Entered Part B | Through Week 28 | Through Week 36 | Through Week 52 |
| --- | --- | --- | --- | --- |
| DT120 ODT 100 µg | “n=76” | “Through Week 28 (n=35)” | “Through Week 36 (n=24)” | “Through Week 52 (n=8)” |
| DT120 ODT 50 µg control | “n=42” | “Through Week 28 (n=19)” | “Through Week 36 (n=10)” | “Through Week 52 (n=3)” |
| Placebo ODT | “n=86” | “Through Week 28 (n=43)” | “Through Week 36 (n=35)” | “Through Week 52 (n=14)” |

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.8.1-4"></a>

##### Part B enrollment in the extension population

| Part A group | Participants |
| --- | --- |
| DT120 ODT 100 µg | “n=62” |
| DT120 ODT 50 µg control | “n=33” |
| Placebo ODT | “n=68” |
| Total | “n=163” |

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="heading-3.1.2.8.2"></a>

#### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

##### Baseline HAM-A score

> “The mean baseline HAM-A score at study entry was 28.3 in the DT120 ODT 100 µg treatment group (n=96) and 28.0 in the placebo group (n=97).”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-3.1.2.8.2-2"></a>

##### Demographics and baseline characteristics, ITT population

| Characteristic | DT120 ODT 100 µg (n=96) | DT120 ODT 50 µg control (n=52) | Placebo ODT (n=97) | Overall (n=245) |
| --- | --- | --- | --- | --- |
| Mean age (years) | “39.8” | “40.4” | “42.3” | “40.9” |
| Sex (% female) | “62%” | “56%” | “62%” | “60%” |
| Race (% white) | “82%” | “85%” | “84%” | “83%” |
| Baseline HAM-A score, mean (SD) | “28.3 (5.5)” | “27.7 (4.8)” | “28.0 (5.6)” | “28.0 (5.4)” |
| Baseline CGI-S score, mean (SD) | “4.7 (0.5)” | “4.7 (0.6)” | “4.7 (0.6)” | “4.7 (0.6)” |
| Past use of any psychedelic, n (%) | “11 (12%)” | “8 (15%)” | “16 (17%)” | “35 (14%)” |
| Past use of LSD, n (%) | “4 (4%)” | “4 (8%)” | “8 (8%)” | “16 (7%)” |

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.8.2-3"></a>

##### Disease severity, treatment history, and comorbidity, ITT population

| Characteristic | DT120 ODT 100 µg (n=96) | DT120 ODT 50 µg control (n=52) | Placebo ODT (n=97) | Overall (n=245) |
| --- | --- | --- | --- | --- |
| HAM-A moderate (<24), n (%) | “20 (21%)” | “9 (17%)” | “27 (28%)” | “56 (23%)” |
| HAM-A severe (≥24), n (%) | “76 (79%)” | “43 (83%)” | “70 (72%)” | “189 (77%)” |
| No past GAD treatments, n (%) | “29 (30%)” | “14 (27%)” | “17 (18%)” | “60 (25%)” |
| One past GAD treatment, n (%) | “20 (21%)” | “15 (29%)” | “22 (23%)” | “57 (23%)” |
| Two or more past GAD treatments, n (%) | “47 (49%)” | “23 (44%)” | “58 (60%)” | “128 (52%)” |
| Comorbid MDD, n (%) | “28 (29%)” | “17 (33%)” | “25 (26%)” | “70 (29%)” |
| MADRS score, mean (SD) | “13.3 (4.4)” | “13.4 (4.5)” | “13.5 (3.9)” | “13.4 (4.2)” |
| Years since diagnosis of GAD, mean (SD) | “6.9 (7.6)” | “9.4 (11.4)” | “9.9 (8.8)” | “8.6 (9.0)” |
| Years since onset of GAD symptoms, mean (SD) | “16.4 (12.6)” | “18.2 (15.5)” | “19.1 (13.4)” | “17.8 (13.6)” |

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.8.2-4"></a>

##### Characteristics at Part B entry

| Characteristic | DT120 ODT 100 µg (n=62) | DT120 ODT 50 µg control (n=33) | Placebo ODT (n=68) | Total (n=163) |
| --- | --- | --- | --- | --- |
| Mean age (years) | “39.5” | “42.3” | “42.8” | “41.4” |
| Sex, female (%) | “62.9%” | “51.5%” | “58.8%” | “58.9%” |
| Race (% white) | “82.3%” | “87.9%” | “83.8%” | “84.0%” |
| HAM-A score at Part B entry | “18.3” | “21.6” | “23.3” | “21.1” |
| CGI-S score at Part B entry | “3.7” | “4.0” | “4.2” | “4.0” |

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="heading-3.1.2.8.3"></a>

#### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

##### Primary endpoint: change in HAM-A total score at Week 12

> “The Least Squares (LS) mean change from baseline in HAM-A total score at Week 12 in participants who received DT120 ODT 100 µg was -9.8 compared with -4.7 for participants who received placebo, an LS mean difference of -5.1 points (p<0.0001), corresponding to a standardized effect size of d=0.64. Efficacy was rapid, with changes seen as early as Day 2 and sustained at all post-baseline timepoints in Part A.”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

> “The LS mean change from baseline in HAM-A total score at Week 12 in participants who received DT120 ODT 100 µg was -9.8 compared with -4.7 for participants who received placebo, an LS mean difference of -5.1 points (p<0.0001), corresponding to a standardized effect size of d=0.64.”

Source: [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm)

<a id="topic-3.1.2.8.3-2"></a>

##### Primary, key secondary, and other secondary endpoints

| Endpoint | DT120 ODT 100 µg | Placebo ODT | Placebo-adjusted difference |
| --- | --- | --- | --- |
| HAM-A: LS mean change at Week 12 (primary) | “-9.8” | “-4.7” | “-5.1 (p<0.0001)” |
| CGI-S: LS mean change at Week 12 (key secondary) | “-1.0” | “-0.5” | “-0.6 (p<0.0001)” |
| HAM-A: LS mean change at Week 1 (key secondary) | “-9.8” | “-4.5” | “-5.3 (p<0.0001)” |
| CGI-S: LS mean change at Day 2 (key secondary) | “-1.1” | “-0.3” | “-0.8 (p<0.0001)” |
| HAM-A response rate (≥50%) at Week 12 | “32%” | “14%” | “18% (p<0.05)” |
| HAM-A remission rate (≤7) at Week 12 | “15%” | “4%” | “12% (p<0.05)” |
| HAM-A mild or better (<16) at Week 12 | “35%” | “17%” | “19% (p<0.01)” |

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

> “Calculated differences may not equal the arithmetic differences between displayed values due to rounding.”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-3.1.2.8.3-3"></a>

##### HAM-A change by visit, 100 µg and 50 µg arms

| Visit | 100 µg: change from baseline | 50 µg: change from baseline | 100 µg: improvement over placebo | 50 µg: improvement over placebo |
| --- | --- | --- | --- | --- |
| Week 1 | “-9.8” | “-10.3” | “-5.3” | “-5.8” |
| Week 4 | “-12.3” | “-8.8” | “-7.0” | “-3.5” |
| Week 8 | “-10.4” | “-8.1” | “-5.3” | “-3.0” |
| Week 12 | “-9.8” | “-8.3” | “-5.1” | “-3.6” |

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.8.3-4"></a>

##### CGI-S change by visit, 100 µg and 50 µg arms

| Visit | 100 µg: change from baseline | 50 µg: change from baseline | 100 µg: improvement over placebo | 50 µg: improvement over placebo |
| --- | --- | --- | --- | --- |
| Day 2 | “-1.1” | “-1.1” | “-0.8” | “-0.8” |
| Week 1 | “-1.2” | “-1.3” | “-0.7” | “-0.8” |
| Week 4 | “-1.4” | “-1.2” | “-1.0” | “-0.7” |
| Week 12 | “-1.1” | “-0.9” | “-0.6” | “-0.4” |

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.8.3-5"></a>

##### Odds ratios for response, remission, and mild or better at Week 12

| Outcome at Week 12 | Odds ratio, DT120 ODT 100 µg vs placebo |
| --- | --- |
| Response (HAM-A ≥ 50% improvement) | “Odds ratio: 2.9” |
| Remission (HAM-A ≤ 7) | “Odds ratio: 4.2” |
| Mild or better (HAM-A < 16) | “Odds ratio: 2.6” |

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.8.3-6"></a>

##### DT120 ODT 50 µg control arm

> “Panorama included a DT120 ODT 50 µg control arm (n=52) that was not designed or powered for statistical comparisons. Consistent with the dose-response profile demonstrated in our Phase 2b trial, DT120 ODT 50 µg demonstrated a placebo-adjusted change of -3.5 and -3.6 at Weeks 4 and 12, approximately 50% and 29% lower than was observed for DT120 ODT 100 µg.”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-3.1.2.8.3-7"></a>

##### Treatment guess and functional unblinding

> “91% and 95% of participants at 50 and 100 µg correctly guessed assignment to drug”
> “Results support the conclusion that DT120 dose response is not attributable to functional unblinding”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.8.3-8"></a>

##### Subgroups analyzed for HAM-A change at Week 12

> “Treatment Effect Maintained Across Key Subgroups”
> “Less than two (n=88)”
> “Two or more (n=105)”
> “Male (n=74)”
> “Female (n=119)”
> “<22 yrs (n=135)”
> “>22 yrs (n=58)”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.8.3-9"></a>

##### Pooled standard deviation of the primary endpoint

| Item | Panorama |
| --- | --- |
| Primary endpoint, DT120 vs placebo | “-5.1” |
| Design | “3 arms” |
| Baseline HAM-A | “28.0” |
| Baseline MADRS | “13.4” |
| Pooled endpoint SD | “8.4” |

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.8.3-10"></a>

##### Part B interim analysis: response, remission, and mild or better through Week 28

| Visit | Participants (n) | HAM-A improvement ≥ 50% | HAM-A ≤ 7 | HAM-A < 16 |
| --- | --- | --- | --- | --- |
| Week 12 | “87” | “32%” | “15%” | “36%” |
| Week 16 | “66” | “23%” | “12%” | “32%” |
| Week 20 | “49” | “51%” | “18%” | “53%” |
| Week 24 | “35” | “60%” | “34%” | “66%” |
| Week 28 | “27” | “48%” | “19%” | “59%” |

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

> “Based on interim analysis as of August 11, 2026. ITT Part A+B population. Interim analysis based on partial data and subject to change.”
> “Only includes participants who received DT120 ODT in Part A.”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="heading-3.1.2.8.4"></a>

#### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.2.8.4-1"></a>

##### Patient-reported and functional outcomes registered for Part A

> “Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in Patient Global Impression - Severity (PGI-S) Scale score”
> “The WPAI-SHP is a 6-item questionnaire, with a recall period of the past 7 days. The WPAI measures impairments in both paid work and unpaid work. It measures absenteeism, presenteeism as well as impairment in unpaid activity because of the health problem under study.”
> “The EuroQol 5 Dimension 5 Level (EQ-5D-5L) is a self-reported outcome measure used to evaluate health outcomes over a wide range of health conditions and treatments.”
> “The CSFQ-14 is a structured self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning”

Source: [ClinicalTrials.gov NCT06809595](https://clinicaltrials.gov/study/NCT06809595)

<a id="topic-3.1.2.8.4-2"></a>

##### Results of patient-reported outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

#### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

##### Overview of adverse events in Part A

| Adverse event | DT120 ODT 100 µg (n=96) | DT120 ODT 50 µg control (n=51) | Placebo ODT (n=97) |
| --- | --- | --- | --- |
| Any TEAE | “91 (95%)” | “49 (96%)” | “61 (63%)” |
| Mild | “51 (53%)” | “29 (57%)” | “30 (31%)” |
| Moderate | “39 (41%)” | “19 (37%)” | “29 (30%)” |
| Severe | “1 (1%)” | “1 (2%)” | “2 (2%)” |
| Any study drug-related TEAE | “90 (94%)” | “47 (92%)” | “34 (35%)” |
| Any adverse event of special interest (AESI) | “84 (88%)” | “43 (84%)” | “31 (32%)” |
| Any SAE | “2 (2%)” | “1 (2%)” | “1 (1%)” |
| Any treatment-related SAE | “0” | “0” | “0” |
| Any TEAE leading to discontinuation | “0” | “0” | “0” |
| Any TEAE leading to death | “0” | “0” | “0” |

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

> “All SAEs were deemed unrelated to the study drug.”
> “Adverse events were collected in accordance with FDA Final Guidance for Psychedelic Drug Development, which includes expected effects characterized as positive, favorable, or neutral.”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.8.5-2"></a>

##### Tolerability summary and overall TEAE rates

> “DT120 ODT 100 μg was generally well tolerated, with most treatment-emergent adverse events (TEAEs) mild to moderate in severity, transient, and predominantly occurring on the day of dosing. No new safety signals were identified, including no suicidality signal or suicidal behavior. There were no drug-related serious adverse events.”
> “The overall TEAE rate for DT120 ODT 100 μg, DT120 50 μg, and placebo was 94.8%, 96.1%, and 62.9%. The most common TEAEs (>10%) in the DT120 ODT 100 μg and 50 μg arms on dosing day were illusion (68%, 61%), nausea (37%, 26%), and headache (24%, 28%).”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

> “There were no drug-related serious adverse events in Part A.”

Source: [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm)

<a id="topic-3.1.2.8.5-3"></a>

##### TEAEs with incidence of 10% or more in the 100 µg arm, on and after dosing day

| TEAE | Dosing day: 100 µg (n=96) | Dosing day: 50 µg (n=51) | Dosing day: placebo (n=97) | After dosing day: 100 µg (n=96) | After dosing day: 50 µg (n=51) | After dosing day: placebo (n=97) |
| --- | --- | --- | --- | --- | --- | --- |
| Illusion | “65 (68%)” | “31 (61%)” | “12 (12%)” | “3 (3%)” | “0” | “0” |
| Nausea | “35 (37%)” | “13 (26%)” | “4 (4%)” | “2 (2%)” | “4 (8%)” | “1 (1%)” |
| Headache | “23 (24%)” | “14 (28%)” | “13 (13%)” | “13 (14%)” | “6 (12%)” | “10 (10%)” |
| Euphoric mood | “30 (31%)” | “16 (31%)” | “5 (5%)” | “1 (1%)” | “0” | “0” |
| Fatigue | “22 (23%)” | “5 (10%)” | “6 (6%)” | “7 (7%)” | “1 (2%)” | “4 (4%)” |
| Dizziness | “22 (23%)” | “10 (20%)” | “3 (3%)” | “1 (1%)” | “1 (2%)” | “0” |
| Anxiety | “16 (17%)” | “7 (14%)” | “7 (7%)” | “6 (6%)” | “3 (6%)” | “5 (5%)” |
| Crying | “20 (21%)” | “6 (12%)” | “0” | “0” | “1 (2%)” | “0” |
| Feeling cold | “14 (15%)” | “2 (4%)” | “6 (6%)” | “0” | “0” | “1 (1%)” |
| Paraesthesia | “13 (14%)” | “4 (8%)” | “3 (3%)” | “0” | “1 (2%)” | “1 (1%)” |
| Time perception altered | “13 (14%)” | “4 (8%)” | “1 (1%)” | “0” | “0” | “0” |
| Feeling of relaxation | “12 (13%)” | “8 (16%)” | “11 (11%)” | “1 (1%)” | “0” | “0” |
| Inappropriate affect | “12 (13%)” | “4 (8%)” | “0” | “0” | “0” | “0” |
| Feeling hot | “11 (12%)” | “4 (8%)” | “4 (4%)” | “0” | “0” | “0” |
| Emotional disorder | “8 (8%)” | “3 (6%)” | “3 (3%)” | “3 (3%)” | “0” | “0” |
| Feeling abnormal | “10 (10%)” | “7 (14%)” | “4 (4%)” | “0” | “0” | “1 (1%)” |
| Restlessness | “10 (10%)” | “1 (2%)” | “3 (3%)” | “1 (1%)” | “0” | “1 (1%)” |
| Tremor | “10 (10%)” | “4 (8%)” | “1 (1%)” | “1 (1%)” | “0” | “0” |

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.8.5-4"></a>

##### Mechanism-based adverse event categories

| Category | DT120 ODT 100 µg | DT120 ODT 50 µg |
| --- | --- | --- |
| Perceptual changes | “87%” | “78%” |
| Affective changes | “66%” | “65%” |
| Behavioral changes | “18%” | “4%” |
| Changes in thinking | “27%” | “35%” |

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

> “Mechanism-based adverse event rates based on number of participants experiencing in Part A; safety population.”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.8.5-5"></a>

##### Suicidality

> “No suicidal or self-injurious behavior”
> “No indication of increased suicide-related risk”
> “Participant suicidality assessment based on changes in C-SSRS.”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.8.5-6"></a>

##### Time to meet end-of-session checklist criteria

> “The average time to meet EoSC criteria was 6.2 hours for participants receiving DT120 ODT 100 μg, with a median of 6.0 hours and 94% of participants meeting EoSC criteria by hour 8. Across over 1,000 treatment sessions in the Phase 3 program through September 10, 2026, 97% of participants met EoSC criteria by hour 8.”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

| Hour after dosing | Panorama, Part A (n=96) | All phase 3 studies (n=1,061 sessions) |
| --- | --- | --- |
| Hour 5 | “45%” | “48%” |
| Hour 6 | “66%” | “66%” |
| Hour 7 | “88%” | “87%” |
| Hour 8 | “94%” | “97%” |

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.8.5-7"></a>

##### Safety in Part B

> “Part B safety data are expected to be shared in a future presentation.”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="heading-3.1.2.9"></a>

### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

#### Summary

Panorama randomized 245 participants 2:1:2 to a single dose of DT120 ODT 100 µg (96), DT120 ODT 50 µg (52), or placebo (97), and its primary analysis compares the 100 µg arm with placebo only. The 50 µg arm was not designed or powered for statistical comparisons, so the placebo-adjusted changes of -3.5 at Week 4 and -3.6 at Week 12 in that arm, and the dose-response statements built on them, carry no hypothesis test. The primary endpoint difference of -5.1 points (d=0.64) exceeds the 2.5-point minimal clinically important difference used in the phase 2b trial and the sponsor's 4-point target product profile; in the presentation's comparison of its trials, Panorama had a pooled endpoint standard deviation of 8.4. The study had no active comparator.

The 50 µg arm was included to mitigate functional unblinding, yet 91% (50 µg) and 95% (100 µg) of participants correctly guessed assignment to drug; no placebo-arm guess rate was reported. HAM-A ratings were made by central raters blinded to treatment assignment and visit number, and FDA guidance states that functional unblinding can lead to expectation bias. The sponsor states that the results support the conclusion that the dose response is not attributable to functional unblinding.

The results come from sponsor topline disclosures (an announcement, a slide presentation, and a Form 10-Q), the registry record lists no results posted, and one author states that adoption will depend on full peer-reviewed reporting of the Voyage and Panorama topline results. These disclosures report no confidence intervals for the primary or key secondary endpoints. Response, remission, and mild-or-better rates (32% vs 14%, 15% vs 4%, 35% vs 17%) are other secondary endpoints outside the multiplicity-controlled key secondary endpoints. Subgroup analyses cover the 100 µg and placebo arms only, and the presentation states that small subgroups give unstable estimates. Patient-reported, functional, quality of life, and sexual functioning outcomes (PGI-S, WPAI-SHP, EQ-5D-5L, CSFQ-14) are registered but unreported.

Part B results come from an interim analysis as of August 11, 2026, based on partial data and subject to change, with open-label dosing and declining numbers of participants (87 at Week 12 and 27 at Week 28 in the response analysis); the 50 µg cohort was excluded for small numbers. The presentation reports two Part B denominators, 204 participants entering Part B (76, 42, and 86 by Part A group) and an extension population of 163 (62, 33, and 68), without stating how they differ. The sponsor states that Part B safety data are expected in a future presentation.

The enrolled population was 60% female and 83% white, aged 18 to 74 years, excluded a current major depressive episode, substance use disorder, and psychotic or bipolar disorder in the participant or a first-degree relative, and excluded systematic psychotherapy within 4 weeks before screening. The psychedelic use exclusion was later amended to any lifetime use; 35 participants (14%) reported past use of any psychedelic and 16 (7%) past use of LSD. Treatment history differed between arms: 60% of placebo participants and 49% of 100 µg participants had two or more past GAD treatments. Enrollment exceeded the target of 200 participants set after a blinded sample size re-estimation. The company reports approximately 32 study centers while the registry lists 36 locations. Participants were monitored for at least 8 hours on dosing day, and 94% of the 100 µg arm met end-of-session checklist criteria by hour 8. The methods report states that Definium Therapeutics funded the study and that all of its authors are company employees.

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder); [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf); [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm); [ClinicalTrials.gov NCT06809595](https://clinicaltrials.gov/study/NCT06809595); [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf); [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/); [FDA psychedelic drugs clinical investigations guidance (2026)](https://www.fda.gov/media/169694/download); [Definium Therapeutics Investor and Analyst Day announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/223/definium-therapeutics-highlights-dt120-odt-lysergide-tartrate-clinical-advancements-and-commercial-strategy-at-investor-and-analyst-day); [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf); [Cubała (2026)](https://pubmed.ncbi.nlm.nih.gov/42848417/)

<a id="topic-3.1.2.9-2"></a>

#### Functional unblinding in psychedelic trials

> “Functional unblinding can lead to expectation bias in the patients who experience perceptual disturbances, or in those who observe them, which may lead to an expectation that the participant will experience clinical benefit; alternatively, those who receive a placebo and do not experience or observe a perceptual change may expect that the participant will not benefit.”
> “Study results should be strongly persuasive and robust across study endpoints to overcome biases that may be introduced by functional unblinding.”

Source: [FDA psychedelic drugs clinical investigations guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="topic-3.1.2.9-3"></a>

#### Interim status of Part B data

> “Based on interim analysis as of August 11, 2026. Interim analysis based on partial data and subject to change.”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-3.1.2.9-4"></a>

#### Funding and authorship of the methods poster

> “The study was funded by Definium Therapeutics, Inc.”
> “All authors are employees of Definium Therapeutics, Inc.”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

Additional sources: [Definium Therapeutics NEI Fall Congress announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/257/definium-therapeutics-presents-topline-phase-3-data-for-dt120-odt-in-generalized-anxiety-disorder-and-major-depressive-disorder-at-2026-nei-fall-congress)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
